NASDAQ:ANGO - AngioDynamics Stock Price, Forecast & News

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Tuesday, January, 7th. The medical instruments supplier reported $0.06 EPS for the quarter, topping the consensus estimate of $0.02 by $0.04. The medical instruments supplier had revenue of $70 million for the quarter, compared to analyst estimates of $71.28 million. AngioDynamics had a net margin of 17.47% and a return on equity of 3.72%. The company's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.22 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Tuesday, April 7th 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics issued an update on its FY20 earnings guidance on Tuesday, January, 7th. The company provided earnings per share (EPS) guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.13. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.85 million.

1 equities research analysts have issued 12 month price targets for AngioDynamics' shares. Their forecasts range from $21.00 to $21.00. On average, they anticipate AngioDynamics' stock price to reach $21.00 in the next year. This suggests a possible upside of 44.5% from the stock's current price. View Analyst Price Targets for AngioDynamics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Media coverage about ANGO stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AngioDynamics earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for AngioDynamics.

AngioDynamics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,350,000 shares, an increase of 35.0% from the December 15th total of 1,000,000 shares. Based on an average daily trading volume, of 338,800 shares, the days-to-cover ratio is currently 4.0 days. Approximately 3.7% of the company's shares are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Intel (INTC), General Electric (GE), Oasis Petroleum (OAS), Cal-Maine Foods (CALM), FireEye (FEYE), Mattel (MAT), Verizon Communications (VZ), Pattern Energy Group (PEGI), Bank of America (BAC) and Centurylink (CTL).

AngioDynamics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (1.73%), Assenagon Asset Management S.A. (0.76%), First National Bank of Omaha (0.11%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for AngioDynamics.

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and First National Bank of Omaha. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $14.53.

AngioDynamics has a market capitalization of $546.76 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]